INVESTMENTS (Tables)

12 Months Ended

Dec. 31, 2025

Investments, All Other Investments [Abstract]

Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis

The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):

	December 31, 2025
	Cost		Unrealized Gains		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities
Cash and cash equivalents, excluding money market accounts	$	50,187	$	—	$	—	$	50,187	$	50,187	$	—
Level 1:
Money market accounts	39,116		—		—		39,116		39,116		—
Government & agency securities	23,247		111		80		23,438		—		23,438
	62,363		111		80		62,554		39,116		23,438
Level 2:
Corporate bonds	53,801		198		533		54,532		—		54,532
Total	$	166,351	$	309	$	613	$	167,273	$	89,303	$	77,970

	December 31, 2024
	Cost		Unrealized Gains (Losses)		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities
Cash and cash equivalents, excluding money market accounts	$	77,551	$	—	$	—	$	77,551	$	77,551	$	—
Level 1:
Money market accounts	13,377		—		—		13,377		13,377		—
Government & agency securities	28,920		15		96		29,031		—		29,031
Equity securities	10,000		(3,939)		—		6,061		—		6,061
	52,297		(3,924)		96		48,469		13,377		35,092
Level 2:
Corporate bonds	35,771		227		326		36,324		—		36,324
Total	$	165,619	$	(3,697)	$	422	$	162,344	$	90,928	$	71,416

Summary of Investment Gains

The gains and losses related to the Company’s LifeMD investment for the year ended December 31, 2025, 2024, and 2023 are summarized in the table below (in thousands):

	Twelve months ended December 31,
	2025		2024		2023
Net gains (losses) recognized during the period on equity securities	$	3,222	$	(4,089)	$	150
Less: Net gains (losses) recognized on equity securities sold	3,222		—		—
Unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date	$	—	$	(4,089)	$	150